Benefits of curing hepatitis C infection

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 1, 2014, Pages 85-90

  Marinho, Rui Tato ^a   Vitor, Sofia ^a   Velosa, José ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

ABT 450; Boceprevir; Chronic hepatitis C; Cirrhosis; Hepatocellular carcinoma; Interferon alpha; Liver transplantation; Ribavirin; Simeprevir; Sofosbuvir; Telaprevir; Therapy

Indexed keywords

ABT 450; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BOCEPREVIR; FALDAPREVIR; GAMMA GLUTAMYLTRANSFERASE; INTERFERON; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS C, CHRONIC; LIVER NEOPLASMS; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 84897079422     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20-29.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29 Suppl 1:74-81.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
4. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 Suppl 2:30-60.
5. Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat 2013;20:550-555.
6. Kershenobich D, Razavi HA, Sánchez-Avila JF, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011;31 Suppl 2:18-29.
7. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31 Suppl 2:61-80.
8. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9:34.
9. Afdhal NH, Zeuzem S, Schooley RT, et al; New Paradigm of HCV Therapy Meeting Participants. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat 2013;20:745-760.
10. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140:1182-1188.e1.
11. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-521.
12. Ferenci P, Fried M, Labrecque D, et al; World Gastroenterology Organisation Guidelines and Publications Committee. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010;19:311-317.
13. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744-749.
14. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-1310.
15. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
16. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
18. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
19. McHutchinson JG, Lawitz EJ, Shi-man NL, et al. IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl Med 2009; 361:580-593.
20. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
21. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-1303.
22. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-662.
23. Lawitz E, Poordad F, Kowdley KV, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013;59:18-23.
24. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013;369:630-639.
25. Bota S, Sporea I, Popescu A, et al. Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review. J Gastrointestin Liver Dis 2011;20:293-298.
26. Swain MG, Lai MY, Shi-man ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593-1601.
27. Giordanino C, Sacco M, Ceretto S, et al. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. Eur J Gastroenterol Hepatol 2014;26:52-58.
28. Fujiwara K, Allison RD, Wang RY, et al. Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 2013;57:483-491.
29. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881.
30. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med 1995;122:586-591.
31. McHutchison JG, Poynard T, Esteban-Mur R, et al; International Hepatitis Interventional Therapy Group. Hepatic HCV RNA before and aftr treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-693.
32. Garcia-Bengoechea M, Basaras M, Barrio J, et al. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alphainterferon therapy. Am J Gastroenterol 1999;94:1902-1905.
33. Mochizuki K, Kagawa T, Takashimizu S, et al. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C. World J Gastroenterol 2004;10:733-736.
34. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785.
35. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009;49:729-738.
36. Marinho RT, Pinto RM, Santos ML, de Moura MC. Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus. Liver Int 2004;24:413-418.
37. Kee KM, Wang JH, Hung CH, et al. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol 2012;27:1106-1111.
38. Crisan D, Radu C, Grigorescu MD, Lupsor M, Feier D, Grigorescu M. Prospective non-invasive follow-up of liver fibrosis in patients with chronic hepatitis C. J Gastrointestin Liver Dis 2012;21:375-382.
39. D'Ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013;59:251-256.
40. Hézode C, Castéra L, Roudot-Thoraval F, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011;34:656-663.
41. Ahmed R, Salama H, Abdallahel S, et al. Correlation between HCV viraemia and splenic volume in chronic HCV infected patients: an Egyptian study. Arab J Gastroenterol 2012;13:58-64.
42. Macías-Rodríguez MA, Rendón-Unceta P, Martínez-Sierra MC, Teyssiere-Blas I, Díaz-García F, Martín-Herrera L. Prognostic usefulness of ultrasonographic signs of portal hypertension in patients with childpugh stage A liver cirrhosis. Am J Gastroenterol 1999;94:3595-3600.
43. Longo S, Cotella G, Carletta F, Catacchio M, Antonaci S. Perihepatic lymphadenopathy and the response to therapy in chronic hepatitis C patients. J Ultrasound 2010;13:164-167.
44. Grier S, Patel N, Kuo YT, et al. Perihepatic lymph nodes as markers of disease response in patients with hepatitis C-related liver disease: a prospective clinical evaluation. Eur J Gastroenterol Hepatol 2010;22:257-263.
45. Muller P, Renou C, Harafa A, et al. Lymph node enlargement within the hepatoduodenal ligament in patients with chronic hepatitis C reflects the immunological cellular response of the host. J Hepatol 2003;39:807-813.
46. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30:1299-1301.
47. Weissenborn K, Ennen JC, Bokemeyer M, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006;55:1624-1630.
48. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol 2012;57:946-952.
49. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on healthrelated quality of life in chronic hepatitis C. J Hepatol 2004;40:675-681.
50. Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012;57:1379-1390.
51. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 2002;36:401-407.
52. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36(5 Suppl 1): S99-S105.
53. Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:109-113.
54. Liu J, Lin CS, Gan WQ, et al. Effect of healthcare insurance policy on the quality of life of chronic hepatitis C patients receiving interferon α-2a plus ribavirin therapy. Exp Ther Med 2012;3:1062-1066.
55. Ryan Caballes F, Sendi H, Bonkovsky HL. Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int 2012;32:880-893.
56. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci 1998;43:529-533.
57. Koskinas J, Kilidireas C, Karandreas N, et al. Severe hepatitis C virusrelated cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study. Liver Int 2007;27:414-420.
58. Ito A, Kazama T, Ito K, Ito M. Purpura with cold urticaria in a patient with hepatitis C virus infection-associated mixed cryoglobulinemia type III: successful treatment with interferon-beta. J Dermatol 2003;30:321-325.
59. Namba T, Shiba R, Yamamoto T, et al. Successful treatment of HCVrelated cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol 2010;14:372-376.
60. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
61. Nunes J, Tato Marinho R, Raposo J, Velosa J. Influence of hepatitis C virus replication on splenic lymphoma with villous lymphocytes. Acta Med Port 2010;23:941-944.
62. Arcaini L, Merli M, Volpetti S, Rattotti S, Gotti M, Zaja F. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol 2012;2012:638185.
63. Sugiura T, Yamada T, Kimpara Y, Fujita N, Goto K, Koyama N. Effects of pegylated interferon alpha-2a on hepatitis-C-virus-associated glomerulonephritis. Pediatr Nephrol 2009;24:199-202.
64. Goel G, Fomberstein B. Leukocytoclastic vasculitis secondary to erysipelas: an unusual case of noncryoglobulinemic vasculitis in a hepatitis C patient. J Clin Rheumatol 2013;19:282-283.
65. Carvalho-Filho RJ, Narciso-Schiavon JL, Tolentino LH, Schiavon LL, Ferraz ML, Silva AE. Central nervous system vasculitis and polyneuropathy as first manifestations of hepatitis C. World J Gastroenterol 2012;18:188-191.
66. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term follow-up study. Arthritis Rheum 2006;54:3696-3706.
67. Mestre TA, Correia de Sá J, Pimentel J. Multifocal central and peripheral demyelination associated with hepatitis C virus infection. J Neurol 2007;254:1754-1756.
68. Byrnes V, Miller A, Lowry D, et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol 2012;56:549-556.
69. Gerkens S, Nechelput M, Annemans L, et al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat 2007;14:523-536.
70. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012;156:279-290.
71. Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004;22:257-265.
72. Blázquez-Pérez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics 2013;31:919-931.
73. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313.
74. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child- Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51:2069-2076.
75. D'Ambrosio R, Aghemo A, Rumi MG, et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ ribavirin therapy. Antivir Ther 2011;16:677-684.
76. Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response. Dig Dis Sci 2013;58:556-561.
77. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-337.
78. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
79. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684.
80. Morgan TR, Ghany MG, Kim HY, et al; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-844.
81. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013;57:1752-1762.
82. Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012;32 Suppl 1:120-128.
83. Shiratori Y, Ito Y, Yokosuka O, et al; Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-114.
84. Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci 2011;56:1853-1861.
85. Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir afer 2006;11:985-994.
86. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-657.
87. Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005;40:148-156.
88. Huang JF, Yu ML, Lee CM, et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther 2007;25:1029-1037.